Company Filing History:
1 out of 832,912 Years Active: 2001
Title: Annette Huls: Innovator in Histamine Receptor Research
Introduction
Annette Huls is a prominent inventor based in Berlin, Germany. She has made significant contributions to the field of pharmacology, particularly in the development of novel chemical compounds that target histamine receptors. Her work has implications for therapeutic applications, showcasing her innovative spirit and dedication to advancing medical science.
Latest Patents
Annette Huls holds a patent for "Imidazole derivatives as histamine receptor H3 (ANT) agonists." This patent details the preparation and therapeutic uses of novel imidazole derivatives that act as histamine receptor antagonists and/or agonists. The patent also discloses chemical compounds designed for use as histamine receptor H agonists, partial agonists, or antagonists, characterized by general formulas (Ia) or (Ib). These compounds are intended for drug development and include methods for assessing their agonist, partial agonist, or antagonist activity in vivo.
Career Highlights
Throughout her career, Annette Huls has demonstrated a commitment to research and innovation. Her work has led to advancements in understanding histamine receptors and their role in various physiological processes. With a patent portfolio that includes 1 patent, she has established herself as a key figure in her field.
Collaborations
Annette has collaborated with notable researchers such as Jean-Charles Schwartz and Jean-Michel Arrang. These partnerships have enriched her work and contributed to the broader scientific community's understanding of histamine receptor functions.
Conclusion
Annette Huls is a trailblazer in the realm of histamine receptor research, with a focus on developing innovative therapeutic compounds. Her contributions continue to influence the field, and her patent reflects her dedication to advancing medical science.